• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Combination therapy with otilonium bromide and trimebutine maleate demonstrates significant clinical advantages in irritable bowel syndrome patients.奥替溴铵与马来酸曲美布汀联合治疗对肠易激综合征患者显示出显著的临床优势。
Am J Transl Res. 2025 Jun 15;17(6):4859-4866. doi: 10.62347/JFCI2618. eCollection 2025.
2
Acupuncture for treatment of irritable bowel syndrome.针刺疗法治疗肠易激综合征
Cochrane Database Syst Rev. 2012 May 16;2012(5):CD005111. doi: 10.1002/14651858.CD005111.pub3.
3
Physical activity for treatment of irritable bowel syndrome.体力活动治疗肠易激综合征。
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD011497. doi: 10.1002/14651858.CD011497.pub2.
4
Evaluation of the combined use of linaclotide and probiotics on clinical treatment efficacy and quality of life in patients with constipation-predominant irritable bowel syndrome.利那洛肽与益生菌联合使用对以便秘为主的肠易激综合征患者临床治疗效果及生活质量的评估。
Am J Transl Res. 2025 May 15;17(5):3333-3344. doi: 10.62347/GNSB4367. eCollection 2025.
5
Tegaserod for the treatment of irritable bowel syndrome and chronic constipation.替加色罗用于治疗肠易激综合征和慢性便秘。
Cochrane Database Syst Rev. 2007 Oct 17(4):CD003960. doi: 10.1002/14651858.CD003960.pub3.
6
Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.用于治疗肠易激综合征的容积性泻剂、抗痉挛药和抗抑郁药。
Cochrane Database Syst Rev. 2011 Aug 10;2011(8):CD003460. doi: 10.1002/14651858.CD003460.pub3.
7
Tegaserod for the treatment of irritable bowel syndrome.替加色罗用于治疗肠易激综合征。
Cochrane Database Syst Rev. 2004(1):CD003960. doi: 10.1002/14651858.CD003960.pub2.
8
The efficacy and safety of rifaximin for the irritable bowel syndrome: a systematic review and meta-analysis.利福昔明治疗肠易激综合征的疗效和安全性：系统评价和荟萃分析。
Am J Gastroenterol. 2012 Jan;107(1):28-35; quiz 36. doi: 10.1038/ajg.2011.355. Epub 2011 Nov 1.
9
A Refractory, Gas-Predominant Subgroup of Irritable Bowel Syndrome Markedly Improved With Relatively Long-Term Paroxetine Treatment: A Preliminary Study.难治性、以气体为主的肠易激综合征亚组经相对长期的帕罗西汀治疗后显著改善：一项初步研究。
Cureus. 2025 Jun 7;17(6):e85494. doi: 10.7759/cureus.85494. eCollection 2025 Jun.
10
A low FODMAP diet plus traditional dietary advice versus a low-carbohydrate diet versus pharmacological treatment in irritable bowel syndrome (CARIBS): a single-centre, single-blind, randomised controlled trial.低 FODMAP 饮食联合传统饮食建议与低碳水化合物饮食或药物治疗对肠易激综合征的疗效比较（CARIBS）：一项单中心、单盲、随机对照试验。
Lancet Gastroenterol Hepatol. 2024 Jun;9(6):507-520. doi: 10.1016/S2468-1253(24)00045-1. Epub 2024 Apr 18.

本文引用的文献

1
Atractylodes macrocephala-Paeonia lactiflora Class Formula for the Treatment of Irritable Bowel Syndrome: A Systematic Review With Meta-Analysis and Trial Sequential Analysis.白术-芍药类方治疗肠易激综合征：一项Meta分析和试验序贯分析的系统评价
Cureus. 2023 Dec 5;15(12):e49997. doi: 10.7759/cureus.49997. eCollection 2023 Dec.
2
Efficacy and safety of Weichang' an pill combined with Western Medicine on gastrointestinal diseases: a systematic review and Meta-analysis.胃肠疾病中胃肠安丸联合西药治疗的疗效及安全性：系统评价与 Meta 分析。
J Tradit Chin Med. 2023 Oct;43(6):1057-1067. doi: 10.19852/j.cnki.jtcm.20230814.003.
3
Otilonium Bromide acts as a selective USP28 inhibitor and exhibits cytotoxic activity against multiple human cancer cell lines.奥替溴铵作为一种选择性USP28抑制剂，对多种人类癌细胞系具有细胞毒性活性。
Biochem Pharmacol. 2023 Sep;215:115746. doi: 10.1016/j.bcp.2023.115746. Epub 2023 Aug 12.
4
Irritable bowel syndrome: Epidemiology, overlap disorders, pathophysiology and treatment.肠易激综合征：流行病学、重叠障碍、病理生理学和治疗。
World J Gastroenterol. 2023 Jul 14;29(26):4120-4135. doi: 10.3748/wjg.v29.i26.4120.
5
Irritable bowel syndrome and mental health comorbidity - approach to multidisciplinary management.肠易激综合征与精神健康共病——多学科管理方法。
Nat Rev Gastroenterol Hepatol. 2023 Sep;20(9):582-596. doi: 10.1038/s41575-023-00794-z. Epub 2023 Jun 2.
6
Otilonium Bromide Prevents Cholinergic Changes in the Distal Colon Induced by Chronic Water Avoidance Stress, a Rat Model of Irritable Bowel Syndrome.奥替溴铵预防慢性水回避应激诱导的大鼠肠易激综合征模型中远端结肠的胆碱能变化。
Int J Mol Sci. 2023 Apr 18;24(8):7440. doi: 10.3390/ijms24087440.
7
Irritable Bowel Syndrome and the Gut Microbiome: A Comprehensive Review.肠易激综合征与肠道微生物群：综述
J Clin Med. 2023 Mar 28;12(7):2558. doi: 10.3390/jcm12072558.
8
The neurobiology of irritable bowel syndrome.肠易激综合征的神经生物学。
Mol Psychiatry. 2023 Apr;28(4):1451-1465. doi: 10.1038/s41380-023-01972-w. Epub 2023 Feb 2.
9
A Discussion of Whether Various Lifestyle Changes can Alleviate the Symptoms of Irritable Bowel Syndrome.关于各种生活方式的改变是否能缓解肠易激综合征症状的讨论。
Healthcare (Basel). 2022 Oct 12;10(10):2011. doi: 10.3390/healthcare10102011.
10
Inflammatory Bowel Disease: Clinical Diagnosis and Surgical Treatment-Overview.炎症性肠病：临床诊断与外科治疗概述。
Medicina (Kaunas). 2022 Apr 21;58(5):567. doi: 10.3390/medicina58050567.

奥替溴铵与马来酸曲美布汀联合治疗对肠易激综合征患者显示出显著的临床优势。

Combination therapy with otilonium bromide and trimebutine maleate demonstrates significant clinical advantages in irritable bowel syndrome patients.

作者信息

Chen Dingfeng, Ni Dongqiong, Yang Haiyan

机构信息

Department of Gastroenterology, The Affiliated Hospital of Shaoxing University Shaoxing 312000, Zhejiang, China.

出版信息

Am J Transl Res. 2025 Jun 15;17(6):4859-4866. doi: 10.62347/JFCI2618. eCollection 2025.

DOI:10.62347/JFCI2618
PMID:40672632
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12261174/
Abstract

OBJECTIVE

To evaluate the efficacy of combined otilonium bromide (OB) and trimebutine maleate (TM-906) therapy in patients with irritable bowel syndrome (IBS).

METHODS

Data from 105 IBS patients treated at the Affiliated Hospital of Shaoxing University were retrospectively analyzed. Patients were divided into two groups: the control group (n=50), receiving OB alone, and the observation group (n=55), receiving both OB and TM-906. A comprehensive set of data, including treatment efficacy, safety profiles, clinical symptom improvements, serum markers, and quality of life, were collected from both groups.

RESULTS

The observation group exhibited significantly higher treatment efficacy and greater improvement in quality of life compared to the control group (P<0.05). The incidence of adverse reactions was similar between groups (7.27% vs. 6.00%, P>0.05). Additionally, the observation group experienced faster symptom relief and a more substantial reduction in inflammatory markers post-treatment (P<0.05).

CONCLUSIONS

Combined therapy with OB and TM-906 is a safe and effective treatment for IBS, offering quicker symptom relief and substantial improvement in quality of life.

摘要

目的

评估奥替溴铵（OB）与马来酸曲美布汀（TM - 906）联合治疗对肠易激综合征（IBS）患者的疗效。

方法

回顾性分析绍兴文理学院附属医院收治的105例IBS患者的数据。患者分为两组：对照组（n = 50），仅接受OB治疗；观察组（n = 55），接受OB和TM - 906联合治疗。从两组收集了一套全面的数据，包括治疗效果、安全性、临床症状改善情况、血清标志物和生活质量。

结果

与对照组相比，观察组的治疗效果显著更高，生活质量改善更大（P < 0.05）。两组间不良反应发生率相似（7.27%对6.00%，P > 0.05）。此外，观察组治疗后症状缓解更快，炎症标志物下降更明显（P < 0.05）。

结论

OB与TM - 906联合治疗是IBS的一种安全有效的治疗方法，能更快缓解症状并显著改善生活质量。